Publication number: 20250051347
Abstract: A compound as shown in formula I, or an optical isomer thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a tautomer thereof, a mesomer thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture form thereof, a metabolite thereof, a metabolic precursor thereof, or an isotope substitute form thereof. TB is a target recognition/binding portion, L is a linking portion, and U is a ubiquitin protease recognition/binding portion, the three portions being connected by means of chemical bonds. The compound can significantly down-regulate mutated androgen receptor (AR) proteins, and has good inhibitory activity on prostate cancer cell lines.
Type:
Application
Filed:
July 29, 2022
Publication date:
February 13, 2025
Applicant:
Hinova Pharmaceuticals, Inc.
Inventors:
Wu Du, Xinghai Li, Kun Wen, Dekun Qin, Shaohua Zhang, Song Chen, Jingyi Duan, Haibin Lv, Haibo Li, Yu Li, Jinyun He, Muyang Chen, Shijuan Liu, Yiwei Fu, Yikai Guan, Zhilin Tu